Given continued high inflation, the Fed may announce aggressive rate hikes again this week. With recession fears mounting, investing in quality dividend stocks like Walmart (WMT), Pfizer (PFE) and Cigna Corporation (CI) could help generate a steady stream of income. read more….
With higher-than-expected inflation, The Federal Reserve will reduce interest rates to At least 75 basis points at this week’s meetingAnalysts fear the Fed will tighten too much and plunge the economy into recession.
The World Bank The world may be headed for a global recession This is because the three largest economies – the US, China and the Eurozone – are experiencing a slowdown.the United States has already Reported for two consecutive quarters Percentage of GDP decline.
So it may be wise to invest in fundamentally strong dividend stocks Walmart (WMT), Pfizer (PFE), and Cigna Corporation (CIsTo ensure a stable source of income, as a recession is expected to be inevitable.
WMT has retail and wholesale operations worldwide. The company operates through three broad segments: Walmart International; and Sam’s Club. Operates multiple stores and EC sites.
September 7, WMT and the UnitedHealth Group (UNH) announced a first-decade collaboration to provide affordable healthcare services. The collaboration is expected to begin at 15 of her Walmart Health locations in Florida and Georgia in 2023, with plans to expand to new regions over time.
On August 30, 2022, WMT began recruiting Canada-based sellers to join its flagship US marketplace to serve its growing base of monthly online shoppers. The company also said it is focused on expanding its Canadian and U.S. markets and investing in new tools and services for sellers.
In February, WMT declared an annual dividend of $2.24 per share in four quarterly installments of $0.56 per share. The annual dividend yield is 1.68%. The company’s dividend payout has grown at a CAGR of 1.9% over the past three years and a CAGR of 1.9% over the past five years.The company has a record of 48 consecutive years of dividend increases..
For the second quarter ended July 31, 2022, WMT’s total revenue was $152.86 billion, an increase of 8.4% year-over-year. Net income increased 20.4% year-on-year to $5.15 billion and EPS was $1.88, up 23.7% year-on-year.
WMT’s revenue is expected to grow 4.7% year-over-year to $145.73 billion in the third quarter ending October 2022. Consensus EPS is estimated at $1.31 for the quarter. Additionally, WMT has had an impressive surprise earnings performance, beating his EPS estimate in three of the last four quarters.
WMT’s share price is up 12.6% over the past three months and closed its last trading session at $133.19.
WMT’s POWR rating reflects this promising outlook. The company has an overall rating of A, which translates into a strong buy in its proprietary rating system. POWR Ratings evaluate stocks by 118 different factors, each with its own weighting.
WMT has an A grade for sentiment and a B grade for growth, stability and quality. Ranked 8th out of 38 A rated stocks Grocery/Big Retail industry.
In addition to the above, we also offer WMT grades value and momentum. Get all WMT ratings here.
PFE discovers, develops, manufactures, distributes and markets biopharmaceuticals worldwide. We offer medicines and vaccines in various therapeutic areas. The company serves wholesalers, retailers, hospitals, clinics, government agencies, and disease control and prevention centers.
On September 12, PFE and BioNTech SE (BNTX) publication A 30 μg booster dose of the Omicron BA.4/BA.5 bivalent COVID-19 vaccine has been recommended for conditional marketing authorization (cMA) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). rice field. ) For individuals ages 12 and older.
Additionally, on September 7, PFE announced that its investigational Group B Streptococcus (GBS) vaccine candidate received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). pregnancy. New recommendations and designations should benefit the company.
On June 23, PFE declared a quarterly dividend of $0.40 per share of common stock, which was paid to shareholders on September 6. The annual dividend was $1.60 for him. 3.48%. The company’s dividend payout has grown at a CAGR of 5.7% over the past three years and a CAGR of 5.9% over the past five years.The company has a record of 11 consecutive years of dividend increases..
PFE revenues for the second quarter ended July 3 were $27.74 billion, up 46.8% year over year. income from continuing operations Adjusted earnings increased 69.6% year-over-year to $9.88 billion and adjusted earnings increased 93.5% year-over-year to $11.66 billion. The company’s adjusted common stock earnings increased 92.5% from last year to $2.04.
The consensus EPS forecast for the fourth quarter ending December was $1.51, an improvement of 12.3% year over year. Analysts expect him to see $24.79 billion in revenue for the quarter, up 4% year over year. Additionally, PFE has outperformed consensus EPS estimates in each of the last four quarters, which is impressive.
The stock rose slightly during the day to close the last trading session at $46.03.
It’s no surprise that PFE has an A rating overall. This translates into a strong buy in the POWR rating system.
PFE is rated A for value and B for sentiment and quality.Within Medical – Pharmaceuticals In the industry, it ranks 8th out of 164 stocks.
To see additional POWR ratings for PFE growth, momentum, and stability, click here.
WMT shares traded at $134.25 per share on Monday afternoon, up $1.06 (+0.80%). Year-to-date, WMT is down -6.11%, while the S&P 500 Index is up -17.65% over the same period.
About the author: Kritika Sarmah
Her interest in high-risk instruments and passion for writing led Kritika to become an analyst and financial journalist. She has a Bachelor of Commerce degree and currently she is working on the CFA program. With her groundbreaking approach, she aims to help investors identify untapped investment opportunities.
post 3 Dividend Stocks to Buy If the U.S. Goes into a Recession first appeared StockNews.com